QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Writing a PBRER or PSUR for a Biological Medicinal Product

Test your understanding of the concepts covered by How to Write a PBRER or PSUR for a Biological Medicinal Product.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the appropriate role of late-breaking information received after the DLP?

Add it silently to the locked interval tables Ignore it because the DLP has passed Discuss its materiality, preliminary status and any actions separately while preserving the main dataset Recalculate all cumulative exposure without documenting the change

Question 2 of 10 What is a key concern when external biosimilar exposure is included in an analysis?

External biosimilar exposure must always be excluded from all scientific discussion The holder should not include external exposure in its denominator while counting only its own product reports in the numerator All biosimilars must be treated as identical to the reference product for every analysis Switching information is irrelevant if the active substance is the same

Question 3 of 10 A company reports a field correction for an injector lot because some doses may not have been fully delivered. What is the most appropriate interpretation?

It automatically proves molecular loss of efficacy It is a quality or device action that may have safety implications and requires clinical assessment It should be excluded from pharmacovigilance because it is not an adverse reaction It establishes a class-wide risk for all biological medicines

Question 4 of 10 Which measure is most informative for evaluating the effectiveness of an injector risk-minimisation action?

The number of educational letters distributed The number of batches manufactured after the action Observed correct device use and reduction in incomplete-dose complaints after the correction The total number of all adverse events for the active substance

Question 5 of 10 Which action is most appropriate when a device issue is limited to one injector lot and does not support an active-substance safety concern?

Change the active-substance safety profile immediately Continue device-effectiveness monitoring and address the presentation-specific issue through appropriate quality or device actions Close all monitoring because the lot was corrected Attribute the issue to a target-mediated class effect

Question 6 of 10 What is the primary purpose of a PBRER or EU PSUR?

To archive every safety case received during the reporting interval To periodically reassess benefits and risks using new information in the context of cumulative knowledge To replace the risk management plan with a comprehensive safety database extract To document only regulatory actions taken during the reporting interval

Question 7 of 10 Why should lack of efficacy be analysed separately from incomplete injector delivery?

Because device events can never affect treatment outcomes Because apparent treatment failure may result from underexposure caused by device malfunction rather than failure of the molecule's pharmacological effect Because efficacy is not relevant in a safety report Because all device complaints are expected adverse reactions

Question 8 of 10 What additional information is particularly important when interpreting antidrug-antibody positivity?

Only the country in which the sample was collected Assay characteristics, sampling timing, drug tolerance, product sequence and clinical outcomes Only the total number of positive tests The number of manufacturing sites, without clinical information

Question 9 of 10 What is a major limitation that should be considered when using non-interventional data to assess switching between biological products?

Routine-practice studies cannot contain safety information Product identity, switching sequence, assay timing and clinical outcomes may be incompletely captured, with confounding remaining possible Observational studies always provide causal proof Only randomised trials can identify antidrug antibodies

Question 10 of 10 Why should the reference safety information version and date be explicitly stated in the report?

To permit silent replacement of the comparator during drafting To establish the baseline against which new safety information and expectedness are evaluated To demonstrate that all regional product information is identical To eliminate the need to describe regional label differences

QPPV.com

Knowledge Assessment: Writing a PBRER or PSUR for a Biological Medicinal Product

Cookie Settings